Apogee advances APEX Phase 2, eyes Phase 3 start and H2 2026 head-to-head data
Apogee Therapeutics expects APEX Phase 2 Part A 52-week data this month and Part B readout in Q2 2026, with Phase 3 initiation targeted for H2 2026 and interim head-to-head combination therapy data versus Dupixent due in H2 2026. The company holds $902.9 million cash runway into H2 2028 to fund operations.
1. APEX Phase 2 Clinical Updates
APEX Phase 2 Part A for atopic dermatitis is complete with 52-week maintenance data expected this month, followed by a 16-week Part B dose-optimization readout in Q2 2026. Pending positive results and regulatory alignment, Apogee plans to initiate a Phase 3 trial in the second half of 2026 to compare efficacy and dosing frequency versus current standards.
2. Combination and Expansion Trials
A head-to-head Phase 1b study of APG279 (zumilokibart + APG990) versus Dupixent in atopic dermatitis is underway with interim safety, pharmacokinetic, pharmacodynamic and efficacy results anticipated in H2 2026. The company also demonstrated proof-of-concept in a Phase 1b asthma trial and will provide details on asthma and eosinophilic esophagitis expansion trials later this year.
3. Financials and Runway
Apogee ended 2025 with $902.9 million in cash, equivalents and marketable securities, up from $731.1 million a year earlier, providing funding into the second half of 2028. Research and development expenses rose to $214.7 million in 2025 as the company advanced multiple clinical programs, while general and administrative costs increased to $70.9 million to support operational growth.